Abstract：【Objective】To investigate the clinical efficacy of low molecular weight heparin combined with alprostadil in the treatment of patients with hyperlipidemic severe acute pancreatitis(SAP). 【Methods】A total of 92 patients with hyperlipidemic SAP admitted to our hospital from July 2020 to July 2022 were selected and randomly divided into an observation group and a control group using a random number table method, with 46 cases in each group. The control group was treated with alprostadil on the basis of conventional treatment, while the observation group was treated with low molecular weight heparin on the basis of the control group's treatment. The conditions of recovery, Ranson score, Sequential Organ Failure Assessment(SOFA) score, hemorheological indexes [D-dimer(D-D), plasma viscosity, fibrinogen(FIB), platelet aggregation rate], blood lipid levels [low density lipoprotein cholesterol(LDL-C), triglyceride(TG), high density lipoprotein cholesterol(HDL-C)], inflammatory factors [white blood cell count(WBC), tumor necrosis factor-α(TNF-α), procalcitonin(PCT)], and prognosis were compared between the two groups. 【Results】After treatment, the mechanical ventilation time, abdominal pain subsidence time, ICU hospitalization time, and intestinal function recovery time in the observation group were shorter than those in the control group(P<0.05); the Ranson score and SOFA score in both groups were lower than those before treatment, and the observation group was lower than the control group, with significant differences(P<0.05); D-D, plasma viscosity, FIB, platelet aggregation rate in the observation group were lower than those before treatment, and those in the observation group were lower than those in the control group, with significant differences(P<0.05); LDL-C, TG in both groups were lower than those before treatment, HDL-C was higher than those before treatment, LDL-C, TG in the observation group were lower than those in the control group, HDL-C was higher than those in the control group, with significant differences(P<0.05); PCT, TNF-α, WBC in both groups were lower than those before treatment, and those in the observation group were lower than those in the control group(P<0.05). The total incidence of complications and recurrence rate in the observation group were lower than those in the control group, with significant differences(P<0.05). 【Conclusion】 Low molecular weight heparin combined with alprostadil has better clinical efficacy in the treatment of hyperlipidemic SAP, which can promote patient recovery, improve microcirculation, reduce lipids and inflammation, and help improve patient prognosis.
韩晓环, 李梅霞, 吴娜娜. 低分子肝素联合前列地尔治疗高脂血症性SAP患者的临床疗效[J]. 医学临床研究, 2024, 41(3): 389-392.
HAN Xiaohuan, LI Meixia, WU Nana. Clinical Efficacy of Low Molecular Weight Heparin Combined with Alprostadil in the Treatment of Patients with Hyperlipidemic SAP. JOURNAL OF CLINICAL RESEARCH, 2024, 41(3): 389-392.
2024, Vol. 41 
